Do you want to read an article? Please log in or register.
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Hypertension
Related content
Hypertension
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
JAMA Cardiol.
Li J, Wang X, Chen J, Zhang H, Deng A
doi: 10.1001/jamacardio.
Hypertension
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
Hypertension.
Danser AHJ, Epstein M, Batlle D
doi: 10.1161/HYPERTENSIONAHA.
RECOMMENDED
Hypertension
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Hypertension
Semenzato L, Botton J, Drouin J, Baricault B, Vabre C, Cuenot F, Penso L, Herlemont P, Sbidian E, Weill A, Dray-Spira R, Zureik M
doi: 10.1161/HYPERTENSIONAHA.120.16314
Further Publications
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Am Heart J.
Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Feldman A, D'Andréa Saba Arruda G, de Souza AS, de Albuquerque DC, Mazza L, Santos MF, Salvador NZ, Gibson CM, Granger CB, Alexander JH, de Souza OF
doi: 10.1016/j.ahj.2020.05.002.
Hypertension
Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis
Hypertension.
Guo X, Zhu Y, Hong Y
doi: 10.
Cardiovascular Risk and Diseases
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
BMJ.
Hippisley-Cox J, Coupland C, Brindle P
doi: 10.1136/bmj.j2099.
Heart Failure
Association between Renin-Angiotensin-Aldosterone system inhibitor use and COVID-19 Hospitalization and death: A 1,4 million patient Nation-Wide registry analysis
Eur J Heart Fail
Savarese G, Benson L, Sundström J, Lund LH
doi: 10.1002/ejhf.2060
Hypertension
Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives
Am J Hypertens.
Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, Romagnoli M, Tonon L, Cavasin P, Novello S, Scarpa R, Farnia A, De Menis E, Rigoli R, Cinetto F, Pauletto P, Agostini C, Rattazzi M
doi: 10.1093/ajh/hpaa096.
Cardiovascular Risk and Diseases
Ramipril in High Risk Patients with COVID-19
J Am Coll Cardiol.
Amat-Santos IJ, Santos-Martinez S, López-Otero D, Nombela-Franco L, Gutiérrez-Ibanes E, Del Valle R, Muñoz-García E, Jiménez-Diaz VA, Regueiro A, González-Ferreiro R, Benito T, Sanmartin-Pena XC, Catalá P, Rodríguez-Gabella T, Delgado-Arana JR, Carrasco-Moraleja M, Ibañez B, San Román JA
doi: 10.1016/j.jacc.2020.05.040.